Biocompatible de novo indolylchalcones as platelet aggregation inhibition and diabetic wound healing agents

Key Points

• The central aim is to evaluate the effectiveness of biocompatible indolylchalcones as agents for inhibiting platelet aggregation and enhancing diabetic wound healing.
• Investigated the anti-platelet aggregation properties of indolylchalcones.
• Assessed the effects on diabetic wound healing processes.
• Evaluated nitric oxide-mediated mechanisms in the therapeutic actions.
• Indolylchalcones exhibit significant anti-platelet activity.
• Demonstrated acceleration in the healing of diabetic wounds.
• Highlighted potential applications for cardiovascular treatment and diabetes management.